Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
Recently, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have been used for renal anemia, but side effects have also been reported. We report on the association of central hypothyroidism and cholesterol with roxadustat. Based on this case and previous reports, we believe that patients receiving roxadustat should have their thyroid function and cholesterol levels checked regularly.
Authors
- Atsushi Nakagawa (ORCID: https://orcid.org/0000-0002-1700-7861)
- Kengo Furuichi (ORCID: https://orcid.org/0000-0002-7069-0938)
- Serina Kita (ORCID: https://orcid.org/0009-0007-4330-5719)
- Toshitaka Sawamura (ORCID: https://orcid.org/0000-0003-1279-4947)
- Keiji Fujimoto (ORCID: https://orcid.org/0000-0002-7392-8753)
- Hiroshi Okuyama (ORCID: https://orcid.org/0000-0002-6031-0612)
- Mizuki Hayashi
- Takaya Kondo
- Hitoshi Yokoyama
- Shinichiro Nakao
Institutions
- Kanazawa Medical University (JP)
- Asanogawa General Hospital (JP)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/ccr3.9400
- Citations
- 5
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.43